Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 59

1.
2.

CYP2C19 polymorphisms and coronary heart disease risk factors synergistically impact clopidogrel response variety after percutaneous coronary intervention.

Liu T, Yin T, Li Y, Song LQ, Yu J, Si R, Zhang YM, He Y, Guo WY, Wang HC.

Coron Artery Dis. 2014 Aug;25(5):412-20. doi: 10.1097/MCA.0000000000000092.

PMID:
24608794
3.

Association between the microarray-based CYP2C19 genotyping assay and the platelet function test in cardiovascular patients receiving clopidogrel.

Choi JL, Kim BR, Kim JE, Woo KS, Kim KH, Kim JM, Kim MH, Han JY.

Int J Lab Hematol. 2014 Oct;36(5):e80-3. doi: 10.1111/ijlh.12194. Epub 2014 Mar 3. No abstract available.

PMID:
24589079
4.

Impact of CYP2C19 polymorphism and proton pump inhibitors on platelet reactivity to clopidogrel and clinical outcomes following stent implantation.

Hokimoto S, Mizobe M, Akasaka T, Arima Y, Kaikita K, Nakagawa K, Ogawa H.

Thromb Res. 2014 Apr;133(4):599-605. doi: 10.1016/j.thromres.2014.01.003. Epub 2014 Jan 9.

PMID:
24440142
5.

Identifying responsiveness to oral P2Y12 receptor blockers: platelet function assays and genetic tests.

Valgimigli M.

J Cardiovasc Med (Hagerstown). 2013 Dec;14 Suppl 1:S8-S15. doi: 10.2459/JCM.0b013e328364bd25. Review.

PMID:
24378839
6.

Potential clinical utility of genetic and platelet function tests in patients on treatment with clopidogrel.

Cattaneo M.

J Cardiovasc Med (Hagerstown). 2013 Dec;14 Suppl 1:S16-21. doi: 10.2459/JCM.0b013e328364bd3a. Review.

PMID:
24378837
7.

Thrombin-induced platelet-fibrin clot strength: relation to high on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes.

Jeong YH, Bliden KP, Shuldiner AR, Tantry US, Gurbel PA.

Thromb Haemost. 2014 Apr 1;111(4):713-24. doi: 10.1160/TH13-08-0643. Epub 2013 Dec 12.

PMID:
24336898
8.

Response variability to P2Y12 receptor inhibitors: expectations and reality.

Siller-Matula JM, Trenk D, Schrör K, Gawaz M, Kristensen SD, Storey RF, Huber K; EPA (European Platelet Academy).

JACC Cardiovasc Interv. 2013 Nov;6(11):1111-28. doi: 10.1016/j.jcin.2013.06.011. Review.

9.

Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways.

Braun OÖ, Angiolillo DJ, Ferreiro JL, Jakubowski JA, Winters KJ, Effron MB, Duvvuru S, Costigan TM, Sundseth S, Walker JR, Saucedo JF, Kleiman NS, Varenhorst C.

Thromb Haemost. 2013 Dec;110(6):1223-31. doi: 10.1160/TH13-03-0263. Epub 2013 Sep 5.

PMID:
24009042
10.

PON1 Q192R genotype influences clopidogrel responsiveness by relative platelet inhibition instead of on-treatment platelet reactivity.

Li X, Zhang L, Chen X, Qu F, Li J, Ma C, Yang J, Xu B, Wang H, Xu Q, Zhang Y, Li Y, Lu C, Yin T.

Thromb Res. 2013 Oct;132(4):444-9. doi: 10.1016/j.thromres.2013.08.004. Epub 2013 Aug 9.

PMID:
23993903
11.

Defining predictive values using three different platelet function tests for CYP2C19 phenotype status on maintenance dual antiplatelet therapy after PCI.

Zhang HZ, Kim MH, Han JY, Jeong YH.

Platelets. 2014;25(4):285-91. doi: 10.3109/09537104.2013.815340. Epub 2013 Aug 23.

PMID:
23971745
12.

[Relationship between human platelet antigen-1 gene polymorphism and clopidogrel resistance in patients with coronary artery disease].

Tanboğa IH, Can MM, Ozkan A, Tokgöz HC, Akgün T, Koca F, Kurt M, Kaymaz C.

Turk Kardiyol Dern Ars. 2013 Jul;41(5):379-85. doi: 10.5543/tkda.2013.97253. Turkish.

13.

[Relevance of CYP2C19 2 regarding platelet reactivity in patients with acute coronary syndrome treated with clopidogrel].

Cano P, Consuegra-Sánchez L, Conesa P, Torres-Moreno D, Jaulent L, Dau D, Picó F, Villegas M.

Med Clin (Barc). 2014 Jul 7;143(1):6-12. doi: 10.1016/j.medcli.2013.04.042. Epub 2013 Jul 10. Spanish.

PMID:
23850044
14.

Impact of the proton pump inhibitors and CYP2C19*2 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays.

Tsantes AE, Ikonomidis I, Papadakis I, Bonovas S, Gialeraki A, Kottaridi C, Kyriakou E, Kokori S, Douramani P, Kopterides P, Karakitsos P, Lekakis J, Kapsimali V.

Thromb Res. 2013 Aug;132(2):e105-11. doi: 10.1016/j.thromres.2013.06.015. Epub 2013 Jul 2.

PMID:
23830212
15.

P2Y12 receptor gene polymorphism and antiplatelet effect of clopidogrel in patients with coronary artery disease after coronary stenting.

Zoheir N, Abd Elhamid S, Abulata N, El Sobky M, Khafagy D, Mostafa A.

Blood Coagul Fibrinolysis. 2013 Jul;24(5):525-31. doi: 10.1097/MBC.0b013e32835e98bf.

PMID:
23751603
16.

Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients.

Zhang L, Chen Y, Jin Y, Qu F, Li J, Ma C, Yang J, Xu B, Wang H, Li X, Li Y, Zhang Y, Lu C, Yin T.

Thromb Res. 2013 Jul;132(1):81-7. doi: 10.1016/j.thromres.2013.05.006. Epub 2013 May 29.

PMID:
23726091
17.

Cytochrome P450 2B6 and 2C9 genotype polymorphism--a possible cause of prasugrel low responsiveness.

Franken CC, Kaiser AF, Krüger JC, Overbeck K, Mügge A, Neubauer H.

Thromb Haemost. 2013 Jul;110(1):131-40. doi: 10.1160/TH13-01-0021. Epub 2013 Apr 25.

PMID:
23615745
18.
19.

The impact of CYP2C19 genotype on cardiovascular events and platelet reactivity in patients with coronary artery disease receiving clopidogrel.

Tousoulis D, Siasos G, Zaromitidou M, Oikonomou E, Maniatis K, Kioufis S, Kokkou E, Papavassiliou AG, Stefanadis C.

Int J Cardiol. 2013 Sep 30;168(2):1594-6. doi: 10.1016/j.ijcard.2013.01.040. Epub 2013 Feb 10. No abstract available.

PMID:
23402725
20.

Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications.

Grosdidier C, Quilici J, Loosveld M, Camoin L, Moro PJ, Saut N, Gaborit B, Pankert M, Cohen W, Lambert M, Beguin S, Morange PE, Bonnet JL, Alessi MC, Cuisset T.

Am J Cardiol. 2013 Apr 1;111(7):985-90. doi: 10.1016/j.amjcard.2012.12.013. Epub 2013 Jan 19.

PMID:
23340030
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk